NCT03464201已完成2 期
Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study
Grupo Español de Tumores Huérfanos e Infrecuentes8 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2018年4月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
- 试验地点
- 8
- 主要终点
- Overall response rate (ORR)
研究概览
简要总结
The good tolerability profile of enzalutamide, the fact that the administration of steroids is not necessary and the impressive results achieved in prostate cancer, make this drug an ideal candidate to be tested in ovarian granulosa cancer, a tumor that could somehow be considered as "female prostate cancer".
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients who have given written informed consent
- •Women aged 18 years or over
- •Eastern Cooperative Oncology Group (ECOG) ≤ 1
- •Diagnosis of histologically confirmed ovarian granulose carcinoma
- •Availability of sufficient biopsy material for confirmation of the diagnosis by a centralized pathologist and determination of the mutation FOXL2402C→ G(C134W). If this material is not available, principal investigator of the study will confirm eligibility of the patient.
- •Metastatic or unresectable disease
- •Radiologically measurable disease. In case you there is not measurable disease, principal investigator of the study will confirm eligibility of the patient. - - Life expectancy ≥ 12 weeks
- •Patients with adequate hepatic function, defined by: Aspartate transaminase (AST) and alanine aminotransferase (ALT) serum values ≤ 3 x upper limit of normal (except in the presence of metastasis in which case values ≤ 5 x upper limit of normal will be allowed), Total bilirubin values ≤ 1,5 x upper limit of normal
- •Patients with adequate bone marrow function, defined by: Absolute neutrophil count ≥ 1.5 x 109 / L, Platelets ≥100 x 109/L, Hemoglobin ≥ 9 g/dL
- •Patients with adequate renal function: serum creatinine ≤ 1,5 x upper limit of normal
- •Absence of any disability to follow the study protocol
- •Women childbearing potential who are sexually active, not undergoing hysterectomy or double adnexectomy, should follow the following contraceptive indications: Negative Pregnancy Test in serum or urine in the 72 hours before the start of treatment, use of a medically accepted method of contraception during: 2 months prior to the start of study treatment, during the study and up to 3 months after the last dose of treatment.
排除标准
- •Patients with another primary tumor 2 years before beginning the drug under study, with the exception of adequately treated or totally surgically removed cervical carcinoma in-situ or basalioma or superficial bladder carcinoma
- •Patients who have received radical radiotherapy ≤ 4 weeks prior to the start of study treatment or who have not recovered from toxicities of radiotherapy. Palliative radiation therapy for painful bone lesions bone is allowed up to 14 days prior to the beginning of the study treatment
- •History of seizures or any conditions that may predispose to suffer them
- •Current or previously treated brain metastases or disease leptomeningeal.
- •Patients with cardiac insufficiency or heart disease clinically significant including any of the following: History or presence of uncontrolled severe ventricular arrhythmias, clinically significant resting bradycardia, any of the following diseases within 6 months prior to the start of the study drug -Myocardial infarction (MI), severe or unstable angina, coronary revascularization, congestive cardiac insufficiency (CCI), cerebrovascular accident (CVA), transient ischemic accident (TIA)-
- •Patients with altered gastrointestinal function or with gastric disease that significantly alters the absorption of enzalutamide, such as for example: severe ulcer diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, extensive resection (> 1m) of the small bowel or inability to swallow oral medication. The previous partial or total gastrectomy is not an exclusion criterion.
- •Diagnosis of human immunodeficiency virus (HIV) infection.
- •Pregnant or lactating women.
- •Women of childbearing potential not using an effective contraceptive method. - Patients who do not want or can follow the study protocol.
研究组 & 干预措施
Enzalutamide
Experimental
Enzalutamide 160 mg daily p.o. (4 capsules 40mg per day)
干预措施: Enzalutamide 40 MG (Drug)
结局指标
主要结局
Overall response rate (ORR)
时间窗: Up to 6 months
Number of responses according to RECIST 1.1 criteria
次要结局
- Progression-free survival (PFS)(Up to 6 months)
- Incidence of Treatment-Emergent Adverse Events(Up to 6 months)
- Clinical benefit rate(Up to 6 months)
- Overall survival (OS)(Up to 6 months)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate CancerStage III Prostate CancerStage IV Prostate CancerNCT02278185University of Colorado, Denver19
已完成
2 期
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate CancerProstate CancerNCT01875250National Cancer Institute (NCI)38
已完成
2 期
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate CancerProstatic NeoplasmsNCT01288911Astellas Pharma Inc375
已完成
2 期
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate CancerNCT02058706Barbara Ann Karmanos Cancer Institute71
进行中（未招募）
不适用
A trial of the combination treatment enzalutamide and AZD5363 for patients with advanced prostate cancer.EUCTR2013-004091-34-GBThe Royal Marsden NHS Foundation Trust136